From MorningStar Premium on 11 Nov:

We maintain our AUD 18 fair value estimate for no-moat Avita following first-quarter fiscal 2021 results based on an AUD/USD exchange rate of 0.72. U.S.-based RECELL revenue increased 59% on the previous corresponding period to USD 5 million as procedure volumes recovered. Although pandemic restrictions initially saw a significant decline in burns due to lower levels of manufacturing and travel, since April 2020 the company has seen a steady recovery. Procedural volumes in the first quarter increased 27% sequentially to 496. As burns treatment is acute and not elective, it cannot be deferred and the reduction in both hospital duration and treatment costs when using RECELL, as opposed to a skin graft, should underpin its use amid a stretched healthcare system. Therefore, while we continue to monitor the resurgence of COVID-19 in the U.S., we think Avita can sustain the estimated first-quarter run-rate of 770 RECELL units and leave our full-year fiscal 2021 unit sales and revenue forecasts of 3,060 and USD 20 million, respectively, unchanged.

The current U.S. approval of the RECELL system is limited to adult burn wounds, however, the applications are far broader. Pivotal clinical trials are underway, and we still anticipate the roll-out of RECELL to be phased to adults outside burn centres in fiscal 2022, paediatric use and vitiligo treatment in fiscal 2023, and soft-tissue reconstruction in fiscal 2025. Key to our valuation is RECELL achieving 45% market share in adults and 20% in children treated at burn centres in the U.S. by fiscal 2025.

Avita is in a healthy financial position and held USD 66 million in cash and no debt as at Sept. 30, 2020. We forecast the company to report a loss of USD 28 million in fiscal 2021, reducing to USD 14 million in fiscal 2022, before positing a USD 5 million profit in fiscal 2023 alongside positive free cash flow. As such, we do not forecast it to require additional funding or experience any financial distress.